{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059543","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.521500+00:00","generated_at":"2026-06-02T01:41:22.154245+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Aspira Women’s Health stockholders approve all proposals at 2024 annual meeting","bullets":["Elected six directors (Stefanie Cavanaugh, Celeste R. Fralick, Jannie Herchuk, Lynn O’Connor Vos, Nicole Sandford, Winfred Parnell) with >4.1M votes for each.","Advisory say-on-pay approved: 4,189,574 for, 97,653 against, 1,752 abstain.","Amended 2019 Stock Incentive Plan to increase authorized shares by 1,000,000 (total ISOs up to 3,000,000): 4,187,597 for, 98,942 against.","Ratified BDO P.C. as auditor for FY2024: 7,992,912 for, 88,066 against, 12,358 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059543","json":"https://secwatch.observer/filing/0000950170-24-059543.json","markdown":"https://secwatch.observer/filing/0000950170-24-059543.md","text":"https://secwatch.observer/filing/0000950170-24-059543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000095017024059543/0000950170-24-059543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000095017024059543/awh-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:41:22.154245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f3fea77c2414d25af284ce84dbd7a5734e46250","claim":"Aspira Women's Health Inc. shareholders approved Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm at the 2024-05-13 meeting.","evidence_excerpt":"000 shares and increase the maximum number of awards that may be granted as incentive stock options under the 2019 Plan to a total of 3,000,000 shares, as set forth below:  FOR AGAINST ABSTENTIONS BROKER NON-VOTES 4,187,597 98,942 2,440 3,804,357 Proposal 4: Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of BDO USA, LLP (n/k/a BDO P.C.) as the Company’s independent registered public accounting firm for the year ending December 31, 2024, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 7,992,912 88,066 12,358","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000095017024059543/0000950170-24-059543-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-13"}]},{"claim_id":"2a6f33905bc8c4f58f588e496d595ba4a151d2bb","claim":"Aspira Women's Health Inc. shareholders approved Election of Directors at the 2024-05-13 meeting.","evidence_excerpt":"NOMINEE FOR AGAINST ABSTENTIONS BROKER NON-VOTES Stefanie Cavanaugh 4,213,732 69,683 5,564 3,804,357","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000095017024059543/0000950170-24-059543-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-13"}]},{"claim_id":"bb2b3a5dc916be71437af9c9f64a66e74da97097","claim":"Aspira Women's Health Inc. shareholders approved Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2024-05-13 meeting.","evidence_excerpt":"4,214,222 73,859 898 3,804,357 Proposal 2: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 1, 2024, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 4,189,574 97,653 1,752 3,804,357 Proposal 3: Approval of an Amendment to the Aspira Women’s Health Inc.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000095017024059543/0000950170-24-059543-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-13"}]},{"claim_id":"c0dfe81874a752bd1140a740f1c011c4ea9f1bb1","claim":"Aspira Women's Health Inc. shareholders approved Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan at the 2024-05-13 meeting.","evidence_excerpt":"y’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 1, 2024, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 4,189,574 97,653 1,752 3,804,357 Proposal 3: Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan The Company’s stockholders approved an amendment to the Company’s 2019 Stock Incentive Plan (the “2019 Plan”) to increase the number of shares of common stock authorized to be granted under the 2019 Plan by 1,000,000 shares and increase the maximum number of awards that may be granted as incentive stock options under the 2019 Plan to a total of 3,000,000 shares, as set forth below:  FOR AGAINST ABSTENTIONS BROKER NON-VOTES 4,187,597 98,942 2,440 3,804,357 Proposal 4: Ratification of the Selection of the Company’s Independent Registered Public Accou","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000095017024059543/0000950170-24-059543-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-13"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}